Meet Our ARCH K12 Scholars

University of Maryland School of Medicine Announces Inaugural Cohort of ARCH K12 Scholars

The University of Maryland School of Medicine (UMSOM) and the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) are pleased to announce the inaugural cohort of scholars selected for the Advancing Oncologic Research Communities in Health Equity (ARCH) K12 Program.

Funded by the National Cancer Institute through the Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research, the ARCH K12 Program is designed to prepare the next generation of independent oncology investigators committed to advancing cancer prevention, treatment, survivorship, and implementation science while improving health outcomes for patients and communities. The program provides two years of intensive mentorship, protected research time, career development, coursework, and experiential learning to support scholars as they transition to independent research careers.

Following a competitive search, three exceptional early-career investigators were selected as the program's inaugural cohort of scholars.

Meet the Inaugural ARCH Scholars

Shuo Jim Huang, PhD, MPH

Shuo Jim Huang PhD MPH

Shuo Jim Huang PhD MPH is an Assistant Professor in Family and Community Medicine whose research seeks to understand and intervene on how complex social structures impact individual health and care quality across the life course. Their current project as an ARCH K12 Scholar uses GPS-Health (a large-scale, granular, and multidimensional geospatial data platform) with advanced computing methods to link individual-level social resources and hazards to receipt of cancer screening and prevention. Jim earned a PhD in Health Services Research from the University of Maryland researching the impact of redlining on health and trained as a T32 Postdoctoral Scholar in Diabetes and Obesity at the University of Maryland Institute for Health Computing where they led the development of GPS-Health.

Xiaolei Shi, MD, PhD

Xiaolei Shi, MD, PhD

Xiaolei Shi, MD, PhD, recently completed her Hematology/Oncology fellowship at the University of Maryland Medical Center and will join the University of Maryland School of Medicine as an Assistant Professor in Genitourinary Oncology in fall 2026. She earned her PhD in Cancer Biology from UT Southwestern and has built a research focus in metabolomics, translational genomics, biomarker discovery, and early-phase clinical trial development. Her work focuses on biomarker-driven therapeutic strategies for prostate and other genitourinary cancers. She leads multi-institutional translational studies of androgen production, uptake, and conversion (APUC) gene signatures in prostate cancer. Under the mentorship of Dr. Arif Hussain, she is developing a Phase I/II trial evaluating galeterone monohydrochloride in metastatic castration-resistant prostate cancer, incorporating serial circulating tumor DNA profiling to monitor response and resistance. As an ARCH K12 Scholar, Dr. Shi aims to advance biomarker-integrated, equity-informed clinical trials to improve outcomes for patients with advanced prostate cancer.

Madelyn F. Klugman, MD

Madelyn F. Klugman, MD

Madelyn F. Klugman, MD, is a breast medical oncologist and Assistant Professor of Medicine at the University of Maryland Marlene and Stewart Greenebaum Cancer Center. She completed fellowship training in medical oncology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. Her work focuses on improving care delivery for patients with breast cancer and advancing understanding of outcomes in real-world populations. Dr. Klugman has a special interest in improving care for young women with breast cancer, who face unique and unmet needs. As a scholar in the ARCH K12 program, she will work with a multidisciplinary team and community partners to better understand and improve care for premenopausal women receiving ovarian suppression as part of their breast cancer treatment.

Building the Future of Equitable Cancer Research

During the two-year program, ARCH Scholars will receive:

  • 75% protected research time
  • Individualized career development planning
  • Multidisciplinary Faculty Mentoring Committees
  • Training in community-engaged oncology research and health disparities
  • Professional development and leadership training
  • Grant writing and manuscript development
  • Opportunities to collaborate with national experts and present research at scientific meetings

The program is designed to prepare scholars to successfully compete for NIH career development and independent research awards while developing innovative approaches to reducing cancer disparities and improving outcomes across diverse communities.

For more information, visit https://research.umgccc.org/crtec/advancing-oncology-research-communities-health-equity-arch-k12-program.